Hematologic Malignancies

Hematologic Malignancies

The addition of daratumumab to traditional therapies used in the treatment of multiple myeloma was well tolerated and associated with high rates of responses.

The major value of RT is in enhancement of local control. In localized disease, perhaps this is best achieved by using RT for patients treated with less than full-dose/course chemotherapy.

As we examine the question of which patients with DLBCL do not need RT, the first step must be to confine our review to patients who have received optimal chemotherapy.

Two studies presented at the 2014 ASH Meeting addressed whether an interim PET scan during and after an initial therapy can help guide treatment.

Autologous hematopoietic cell transplantation is a safe and effective treatment option for patients with HIV-associated lymphoma, according to a study presented at ASH 2014.

A large trial has shown that adolescents and young adults have better event-free and overall survival when treated on an intensive pediatric ALL regimen.

An oral inhibitor of isocitrate dehydrogenase 2 (IDH2), AG-221, has shown activity and potentially durable remissions in patients with acute myeloid leukemia.


Subscribe to Hematologic Malignancies on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.